J&J Producing Tylenol ‘24-7’ As US OTC Sales Jump 35% On Pandemic-Driven Stockpiling
J&J is prioritizing Tylenol production on caplets easiest to manufacture to maximize output as it manufactures the line around the clock, says CEO Alex Gorsky. First-quarter US OTC sales soared 35% as consumers stockpiled due to COVID-19, though the pandemic led J&J to downgrade its 2020 outlook.
You may also be interested in...
GSK launches Robitussin Naturals drug-free cough and cold remedies in the first naturals offering under the top-selling OTC drug brand. The line includes liquids and gummies for adults and children formulated with honey, ivy leaf and eucalyptus.
Johnson & Johnson skin health includes hard-hit products and products that have seen double-digit sales growth during the pandemic, worldwide chairman of Consumer Health Thibaut Mongon said at the Barclays Global Consumer Staples Conference. He went on to highlight launches that are reinforcing J&J’s lead in therapeutic skin care and reflecting its sustainability push.
Johnson & Johnson US OTC sales a bright spot in a Q2 performance hampered by the COVID-19 pandemic.